Key Activist Investor Throws Shade At Novavax Over COVID-19 Vaccines
Executive Summary
Shah Capital Management said Novavax could tap the estimated 100 million Americans uncomfortable with mRNA vaccines, such as those from Pfizer/BioNTech and Moderna.